COLL

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Peers: AMRX ANIP ARDX ASRT ASND EYPT HRTX LXRX PCRX PTGX

| Held by: IJR IWM VTI CALF SPSM IWO VXF IJT PJP SLYG

Index	RUT	P/E	33.71	EPS (ttm)	1.04	Insider Own	3.18%	Shs Outstand	31.55M	Perf Week	-7.50%
Market Cap	1.10B	Forward P/E	4.51	EPS next Y	7.73	Insider Trans	-10.62%	Shs Float	30.50M	Perf Month	-6.03%
Enterprise Value	1.81B	PEG	-	EPS next Q	1.88	Inst Own	115.70%	Short Float	14.18%	Perf Quarter	19.67%
Income	36.27M	P/S	1.56	EPS this Y	10.33%	Inst Trans	-3.78%	Short Ratio	11.66	Perf Half Y	18.53%
Sales	707.01M	P/B	4.74	EPS next Y	8.68%	ROA	2.74%	Short Interest	4.32M	Perf YTD	21.88%
Book/sh	7.36	P/C	4.55	EPS next 5Y	-0.37%	ROE	16.16%	52W High	42.29 -17.42%	Perf Year	-3.54%
Cash/sh	7.68	P/FCF	5.45	EPS past 3/5Y	0.01% -	ROIC	3.24%	52W Low	23.23 50.32%	Perf 3Y	104.93%
Dividend Est.	-	EV/EBITDA	4.96	Sales past 3/5Y	31.63% 16.31%	Gross Margin	56.69%	Volatility	4.08% 3.01%	Perf 5Y	89.68%
Dividend TTM	-	EV/Sales	2.56	EPS Y/Y TTM	-63.00%	Oper. Margin	21.73%	ATR (14)	1.27	Perf 10Y	124.57%
Dividend Ex-Date	-	Quick Ratio	1.10	Sales Y/Y TTM	22.61%	Profit Margin	5.13%	RSI (14)	40.08	Recom	1.40
Dividend Gr. 3/5Y	- -	Current Ratio	1.18	EPS Q/Q	-34.00%	SMA20	-8.96%	Beta	0.67	Target Price	44.60
Payout	0.00%	Debt/Eq	4.10	Sales Q/Q	29.41%	SMA50	-0.01%	Rel Volume	1.81	Prev Close	37.32
Employees	357	LT Debt/Eq	3.81	Earnings	Aug 07 BMO	SMA200	12.78%	Avg Volume	370.91K	Price	34.92
IPO	May 07, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.92% 3.93%	Trades		Volume	672,016	Change	-6.43%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-10-25	Upgrade	Needham	Hold → Buy	$46
Jul-30-24	Upgrade	H.C. Wainwright	Neutral → Buy	$47
Jun-07-24	Upgrade	Jefferies	Hold → Buy	$41 → $44
May-10-24	Downgrade	Piper Sandler	Overweight → Neutral	$39
May-10-24	Downgrade	Needham	Buy → Hold
Jan-04-24	Downgrade	Jefferies	Buy → Hold	$30 → $37
Aug-25-23	Reiterated	Needham	Buy	$35 → $36
May-02-23	Resumed	Jefferies	Buy	$30
Aug-08-22	Downgrade	H.C. Wainwright	Buy → Neutral
Feb-15-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$18 → $26
Aug-06-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-11-21	Reiterated	H.C. Wainwright	Buy	$29 → $33
Jul-14-20	Initiated	BWS Financial	Sell	$8
May-27-20	Initiated	Guggenheim	Neutral
Feb-19-20	Resumed	Jefferies	Buy	$43
Oct-30-19	Reiterated	Needham	Buy	$33 → $25
May-03-19	Resumed	H.C. Wainwright	Buy	$23
Apr-12-19	Resumed	Janney	Buy	$29
Mar-20-19	Initiated	SunTrust	Hold	$22
Jan-16-19	Reiterated	Needham	Buy	$35 → $33

Show Previous Ratings

Sep-02-25 04:07AM	Collegium Pharmaceutical, Inc. (COLL) to Present 9 Pain Studies at PAINWeek 2025 (Insider Monkey)
Aug-29-25 05:07AM	Collegium Pharmaceutical, Inc. (COLL) Highlights Real-World Evidence at PAINWeek 2025 (Insider Monkey)
Aug-28-25 08:00AM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-25-25 08:00AM	Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting (GlobeNewswire)
Aug-14-25 01:34AM	The 5 Most Interesting Analyst Questions From Collegium Pharmaceutical's Q2 Earnings Call (StockStory)
03:25AM	Loading…
Aug-12-25 03:25AM	COLL Q2 Deep Dive: Jornay Expansion Drives Revenue Guidance Increase, Margins Face Investment Pressure (StockStory)
Aug-11-25 09:33AM	Arm initiated, Adobe downgraded: Wall Street's top analyst calls (The Fly)
Aug-07-25 02:53PM	Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q2 Expectations, Stock Jumps 10.2% (StockStory) +10.72%
09:30AM	Compared to Estimates, Collegium Pharmaceutical (COLL) Q2 Earnings: A Look at Key Metrics (Zacks)
08:50AM	Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates (Zacks)
07:49AM	Collegium Pharmaceutical: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook (GlobeNewswire)
Aug-06-25 05:50PM	Inotiv, Inc. (NOTV) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Aug-05-25 11:11PM	Collegium Pharmaceutical (COLL) Q2 Earnings: What To Expect (StockStory)
10:00AM	Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
10:00AM	Loading…
Jul-31-25 10:00AM	Collegium Pharmaceutical (COLL) Q2 Earnings Preview: What's in the Cards? (Zacks)
Jul-28-25 12:01AM	3 Reasons to Avoid COLL and 1 Stock to Buy Instead (StockStory)
Jul-25-25 09:55AM	Wall Street Analysts See a 33.91% Upside in Collegium Pharmaceutical (COLL): Can the Stock Really Move This High? (Zacks)
09:40AM	Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now? (Zacks)
Jul-24-25 08:00AM	Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire)
Jul-10-25 04:09PM	5 Hot Stocks With Summer Buybacks You Can Cash In On (MarketBeat)
Jul-07-25 08:00AM	Collegium Announces $150 Million Share Repurchase Program (GlobeNewswire)
Jul-01-25 02:42AM	Collegium Pharmaceutical Announces Share Repurchase Program Worth $25 Million (Insider Monkey)
Jun-30-25 06:24AM	5 Insightful Analyst Questions From Collegium Pharmaceutical's Q1 Earnings Call (StockStory)
Jun-10-25 04:40AM	COLL Q1 Earnings Call: ADHD Portfolio Drives Growth, Management Details Capital Deployment Priorities (StockStory)
Jun-05-25 11:31PM	Branded Pharmaceuticals Stocks Q1 In Review: Collegium Pharmaceutical (NASDAQ:COLL) Vs Peers (StockStory)
May-19-25 04:01PM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-12-25 08:05AM	Collegium Announces $25 Million Accelerated Share Repurchase Program (GlobeNewswire)
May-09-25 03:42AM	Collegium Pharmaceutical Inc (COLL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com) +5.94%
May-08-25 05:30PM	Compared to Estimates, Collegium Pharmaceutical (COLL) Q1 Earnings: A Look at Key Metrics (Zacks)
05:15PM	Loading…
05:15PM	Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Surpass Estimates (Zacks)
04:11PM	Collegium Pharmaceutical: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
May-07-25 06:15PM	ElectroCore, Inc. (ECOR) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
05:20PM	Collegium Pharmaceutical Q1 2025 Earnings Preview (Seeking Alpha)
10:28AM	Collegium Pharmaceutical Inc (COLL) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
May-01-25 10:01AM	Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-28-25 12:12PM	Indivior: Trying To Break Addiction (Seeking Alpha)
09:01AM	3 Healthcare Stocks That Concern Us (StockStory)
Apr-24-25 08:00AM	Collegium to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
03:55AM	Third Avenue Small Cap Value Fund Q1 2025 Commentary (Seeking Alpha)
Apr-23-25 09:40AM	Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? (Zacks)
Apr-16-25 02:41PM	IYH: Healthcare Dashboard For April (Seeking Alpha)
Apr-14-25 05:11AM	2 Reasons to Watch COLL and 1 to Stay Cautious (StockStory)
Apr-02-25 05:05AM	A Look Back at Branded Pharmaceuticals Stocks' Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack (StockStory)
Apr-01-25 08:00AM	Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-25 08:00AM	Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine's Annual Meeting (GlobeNewswire)
Mar-26-25 07:00AM	Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board (GlobeNewswire)
Mar-18-25 03:22PM	Teva Pharmaceutical Stock Scores RS Rating Upgrade (Investor's Business Daily)
Mar-17-25 07:00AM	Collegium Announces Updates to its Board of Directors and Executive Leadership Team (GlobeNewswire)
Mar-10-25 06:57PM	Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care (GlobeNewswire)
Mar-04-25 08:00AM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-01-25 06:45AM	Is Collegium Pharmaceutical, Inc. (COLL) the Best Small Cap Pharma Stocks to Buy Now? (Insider Monkey)
Feb-28-25 07:05AM	Q4 2024 Collegium Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
02:37AM	Collegium Pharmaceutical Inc (COLL) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Feb-27-25 07:00PM	Collegium Pharmaceutical (COLL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:45PM	Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Beat Estimates (Zacks)
04:52PM	Collegium Pharmaceutical: Q4 Earnings Snapshot (Associated Press Finance)
04:28PM	Collegium Pharmaceuticals (NASDAQ:COLL) Q4 Sales Top Estimates, Stock Jumps 14.1% (StockStory)
04:01PM	Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results (GlobeNewswire)
Feb-26-25 09:15AM	Seeking Clues to Collegium Pharmaceutical (COLL) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
08:12AM	Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect (StockStory)
07:53AM	What To Expect From Collegium Pharmaceutical Inc (COLL) Q4 2024 Earnings (GuruFocus.com)
Feb-13-25 08:00AM	Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025 (GlobeNewswire)
Feb-05-25 08:00AM	Collegium Appoints Nancy S. Lurker to its Board of Directors (GlobeNewswire)
Jan-09-25 08:30AM	Collegium Pharmaceutical Unveils 2025 Financial Projections (TipRanks)
Jan-08-25 08:00AM	Collegium Provides 2025 Financial Guidance and Business Update (GlobeNewswire) +14.41%
Nov-13-24 09:40AM	Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now? (Zacks)
Nov-12-24 08:00AM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-08-24 10:03AM	Collegium Pharmaceutical Inc (COLL) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) -7.35%
08:34AM	Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock? (Zacks)
Nov-07-24 06:30PM	Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings (Zacks)
05:35PM	Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Lag Estimates (Zacks)
04:34PM	Collegium Pharmaceutical: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Collegium Reports Record Third Quarter 2024 Financial Results (GlobeNewswire)
04:01PM	Collegium Appoints Vikram Karnani as Chief Executive Officer (GlobeNewswire)
Nov-06-24 07:25AM	What To Expect From Collegium Pharmaceutical Inc (COLL) Q3 2024 Earnings (GuruFocus.com)
Oct-31-24 10:01AM	Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-28-24 09:40AM	Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? (Zacks)
Oct-24-24 08:00AM	Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire)
Oct-11-24 09:40AM	Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now? (Zacks)
Oct-09-24 05:55PM	Collegium Pharmaceutical Inc (COLL) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Oct-04-24 02:37PM	Breakouts Boost These Three Stocks To All-Time Highs (Investor's Business Daily)
Sep-25-24 09:40AM	Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? (Zacks)
Sep-09-24 12:00PM	Collegium Pharmaceutical (COLL) Upgraded to Buy: Here's Why (Zacks)
09:40AM	Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? (Zacks)
Sep-07-24 01:28AM	Insider Sale: EVP and General Counsel Shirley Kuhlmann Sells 20,225 Shares of Collegium ... (GuruFocus.com)
Sep-04-24 08:00AM	Collegium Completes Acquisition of Ironshore Therapeutics (GlobeNewswire)
Aug-30-24 08:00AM	Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-28-24 08:00AM	Collegium Announces Eight Poster Presentations at PAINWeek Conference 2024 (GlobeNewswire)
Aug-08-24 09:59PM	COLL Stock Earnings: Collegium Pharmaceutical Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
06:00PM	Collegium Pharmaceutical (COLL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:25PM	Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates (Zacks)
04:20PM	Collegium Pharmaceutical: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Collegium Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-07-24 09:15AM	Unveiling Collegium Pharmaceutical (COLL) Q2 Outlook: Wall Street Estimates for Key Metrics (Zacks)
Aug-01-24 10:01AM	Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy? (Zacks)
06:30AM	Compass Pathways announces second quarter 2024 financial results and business highlights (GlobeNewswire)
Jul-31-24 06:53AM	Collegium Pharmaceutical (COLL) Soars 10.6%: Is Further Upside Left in the Stock? (Zacks)
Jul-30-24 09:33AM	Collegium buys Ironshore for $525m and enter ADHD market (Pharmaceutical Technology) +10.63%

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Smith Thomas B	EVP and Chief Medical Officer	Aug 29 '25	Sale	38.42	17,478	671,576	70,264	Sep 03 04:56 PM
Smith Thomas B	Officer	Aug 29 '25	Proposed Sale	38.42	17,478	671,576		Aug 29 02:12 PM
Dreyer Scott	EVP & Chief Commercial Officer	Aug 18 '25	Option Exercise	21.34	16,389	349,741	120,002	Aug 20 04:57 PM
Dreyer Scott	EVP & Chief Commercial Officer	Aug 18 '25	Sale	38.21	16,389	626,171	103,613	Aug 20 04:57 PM
SANTINI GINO	Director	Aug 15 '25	Option Exercise	13.45	15,000	201,750	100,447	Aug 19 05:10 PM
SANTINI GINO	Director	Aug 15 '25	Sale	37.19	5,405	201,018	95,042	Aug 19 05:10 PM
Dreyer Scott	Officer	Aug 18 '25	Proposed Sale	38.21	16,389	626,170		Aug 18 04:50 PM
Dreyer Scott	EVP & Chief Commercial Officer	Aug 13 '25	Option Exercise	21.34	4,861	103,734	108,474	Aug 15 05:08 PM
Dreyer Scott	EVP & Chief Commercial Officer	Aug 13 '25	Sale	38.03	4,861	184,881	103,613	Aug 15 05:08 PM
Rubric Capital Management LP	10% Owner	Aug 13 '25	Sale	37.85	25,000	946,250	3,132,743	Aug 15 04:12 PM
SANTINI GINO	Director	Aug 15 '25	Proposed Sale	37.19	5,405	201,019		Aug 15 12:34 PM
Dreyer Scott	Officer	Aug 13 '25	Proposed Sale	38.03	4,861	184,881		Aug 13 04:31 PM
Freund John Gordon	Director	Aug 08 '25	Sale	34.36	11,659	400,641	23,129	Aug 12 05:18 PM
Heffernan Michael Thomas	Former Director	Jul 09 '25	Proposed Sale	32.17	10,328	332,269		Jul 09 04:10 PM
Heffernan Michael Thomas	Former Director	Jul 08 '25	Proposed Sale	31.38	790	24,792		Jul 08 04:19 PM
Heffernan Michael Thomas	Former Director	Jul 07 '25	Proposed Sale	31.25	14,210	444,062		Jul 07 04:43 PM
Heffernan Michael Thomas	Former Director	Jul 02 '25	Proposed Sale	30.30	25,000	757,380		Jul 02 04:50 PM
Melincoff Gwen A	Former Director	Jul 02 '25	Proposed Sale	30.29	47,082	1,425,971		Jul 02 04:35 PM
Freund John Gordon	Director	Jun 09 '25	Option Exercise	13.45	15,000	201,750	77,259	Jun 11 05:04 PM
Freund John Gordon	Director	Jun 09 '25	Sale	30.62	6,601	202,149	70,658	Jun 11 05:04 PM
Freund John Gordon	Director	Jun 09 '25	Proposed Sale	30.62	6,601	202,148		Jun 09 01:02 PM
Tupper Colleen	EVP & Chief Financial Officer	Mar 21 '25	Sale	30.03	6,396	192,069	156,667	Mar 24 05:06 PM
Tupper Colleen	EVP & Chief Financial Officer	Mar 20 '25	Sale	30.00	1,206	36,181	163,063	Mar 24 05:06 PM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 21 '25	Sale	30.03	18,881	566,983	103,613	Mar 24 05:05 PM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 20 '25	Sale	30.00	1,927	57,811	122,494	Mar 24 05:05 PM
Tupper Colleen	Officer	Mar 21 '25	Proposed Sale	30.03	6,396	192,069		Mar 21 04:35 PM
Dreyer Scott	Officer	Mar 21 '25	Proposed Sale	30.03	18,881	566,984		Mar 21 04:21 PM
Tupper Colleen	Officer	Mar 20 '25	Proposed Sale	30.00	1,206	36,181		Mar 20 04:32 PM
Kuhlmann Shirley R.	Former Officer	Mar 20 '25	Proposed Sale	29.65	40,494	1,200,632		Mar 20 04:19 PM
Dreyer Scott	Officer	Mar 20 '25	Proposed Sale	30.00	1,927	57,811		Mar 20 04:17 PM
Tupper Colleen	EVP & Chief Financial Officer	Mar 14 '25	Sale	30.00	977	29,313	164,269	Mar 18 05:35 PM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 14 '25	Sale	30.00	2,255	67,661	124,421	Mar 18 05:34 PM
Tupper Colleen	Officer	Mar 14 '25	Proposed Sale	30.00	977	29,313		Mar 14 04:06 PM
Dreyer Scott	Officer	Mar 14 '25	Proposed Sale	30.00	2,255	67,661		Mar 14 03:55 PM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 06 '25	Sale	30.00	15,387	461,672	126,676	Mar 13 04:50 PM
Tupper Colleen	EVP & Chief Financial Officer	Mar 11 '25	Sale	30.01	10,445	313,413	165,246	Mar 13 04:49 PM
Tupper Colleen	Officer	Mar 11 '25	Proposed Sale	30.01	10,445	313,413		Mar 11 04:16 PM
Dreyer Scott	Officer	Mar 11 '25	Proposed Sale	30.00	15,387	461,672		Mar 11 04:08 PM
Tupper Colleen	EVP & Chief Financial Officer	Mar 06 '25	Sale	30.00	1,949	58,470	177,195	Mar 10 04:02 PM
Tupper Colleen	EVP & Chief Financial Officer	Mar 07 '25	Sale	30.00	1,504	45,121	175,691	Mar 10 04:02 PM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 06 '25	Sale	30.00	3,295	98,854	144,411	Mar 10 04:01 PM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 07 '25	Sale	30.00	2,348	70,446	142,063	Mar 10 04:01 PM
Dreyer Scott	Officer	Mar 07 '25	Proposed Sale	30.00	2,348	70,446		Mar 07 04:21 PM
Tupper Colleen	Officer	Mar 07 '25	Proposed Sale	30.00	1,504	45,121		Mar 07 04:13 PM
Kuhlmann Shirley R.	EVP and General Counsel	Mar 04 '25	Option Exercise	24.03	40,000	961,200	194,204	Mar 06 06:48 PM
Kuhlmann Shirley R.	EVP and General Counsel	Mar 04 '25	Sale	28.08	40,000	1,123,160	154,204	Mar 06 06:48 PM
Kuhlmann Shirley R.	EVP and General Counsel	Mar 06 '25	Sale	28.50	26,067	742,946	108,137	Mar 06 06:48 PM
Kuhlmann Shirley R.	EVP and General Counsel	Mar 05 '25	Sale	28.03	20,000	560,528	134,204	Mar 06 06:48 PM
Tupper Colleen	Officer	Mar 06 '25	Proposed Sale	30.00	1,949	58,470		Mar 06 04:43 PM
Dreyer Scott	Officer	Mar 06 '25	Proposed Sale	30.00	3,295	98,854		Mar 06 04:31 PM
Kuhlmann Shirley R.	Officer	Mar 06 '25	Proposed Sale	28.50	26,067	742,946		Mar 06 10:42 AM
Kuhlmann Shirley R.	Officer	Mar 05 '25	Proposed Sale	28.03	20,000	560,528		Mar 05 03:03 PM
Kuhlmann Shirley R.	Officer	Mar 04 '25	Proposed Sale	28.08	40,000	1,123,160		Mar 04 04:16 PM
Kuhlmann Shirley R.	EVP and General Counsel	Jan 10 '25	Option Exercise	21.34	27,500	586,850	146,684	Jan 14 04:12 PM
Kuhlmann Shirley R.	EVP and General Counsel	Jan 10 '25	Sale	33.04	27,500	908,628	119,184	Jan 14 04:12 PM
Kuhlmann Shirley R.	Officer	Jan 10 '25	Proposed Sale	33.04	27,500	908,628		Jan 10 04:14 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Collegium Pharmaceutical Inc

Upgrade your FINVIZ experience